SG/CALL/ASTRAZENECA/9000/0.1/20.12.24 Stock

DE000SU9A8Y8

Market Closed - Boerse Frankfurt Warrants 03:49:27 2024-07-17 pm EDT
4.01 ^EUR	+4.70%

Current month	-1.72%
1 month	-6.56%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart SG/CALL/ASTRAZENECA/9000/0.1/20.12.24

Latest news about ASTRAZENECA PLC

AstraZeneca's Capivasertib Gets UK Marketing Authorization for Advanced Breast Cancer Treatment	Jul. 17	MT
EU court criticizes Commission over handling of COVID vaccine contracts	Jul. 17	RE
Astrazeneca - Acquisition of Amolyt Pharma completed	Jul. 16	AQ
Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...	Jul. 15

More news

Quotes 5-day view

Date	Price	Change
24-07-17	3.99	+4.18%
24-07-16	3.83	+0.52%
24-07-15	3.81	-3.05%
24-07-12	3.93	0.00%
24-07-11	3.93	+5.36%

Real-time Boerse Frankfurt Warrants

Last update July 17, 2024 at 03:49 pm EDT

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Société Générale
WKN	SU9A8Y
ISIN	DE000SU9A8Y8
Date issued	2024-02-14
Strike	9,000 p
Maturity	2024-12-20 (156 Days)
Parity	10 : 1
Emission price	1.52 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	4.62 €
Lowest since issue	1.47 €
Spread	0.28 €
Spread %	6.48%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company